last
centuri
vaccin
effect
medic
intervent
reduc
death
morbid
caus
infecti
diseas
believ
vaccin
save
least
million
live
per
year
worldwid
smallpox
erad
polio
almost
disappear
worldwid
global
vaccin
campaign
viral
bacteri
infect
tradit
affect
children
drastic
reduc
thank
nation
immun
program
develop
countri
howev
mani
diseas
yet
prevent
vaccin
vaccin
fulli
exploit
target
popul
elderli
pregnant
women
review
focus
state
art
recent
clinic
trial
vaccin
major
unmet
medic
need
hiv
malaria
tb
cancer
addit
describ
innov
technolog
current
use
vaccin
research
develop
includ
adjuv
vector
nucleic
acid
vaccin
structurebas
antigen
design
hope
thank
technolog
diseas
address
centuri
novel
prevent
therapeut
vaccin
progress
scienc
alway
major
drive
forc
develop
effect
vaccin
fig
tabl
provid
list
licens
human
vaccin
group
differ
class
base
method
product
review
plotkin
et
al
levin
et
al
de
gregorio
et
al
first
golden
age
vaccin
start
pasteur
koch
ramon
establish
germ
theori
develop
vaccin
base
liveattenu
inactiv
kill
pathogen
inactiv
toxin
toxoid
vaccin
protect
rabi
diphtheria
tetanu
pertussi
tuberculosi
infant
second
golden
age
vaccin
consequ
innov
cell
cultur
technolog
second
half
centuri
cell
cultur
revolut
allow
effect
inactiv
vaccin
prevent
polio
ipv
hepat
liveattenu
vaccin
polio
opv
mump
rubella
measl
mmr
rotaviru
varicella
progress
microbiolog
led
develop
polysaccharid
vaccin
strain
pneumococcu
meningococcu
howev
vaccin
effect
children
improv
immunogen
antigen
polysaccharid
primarili
induc
bcelldepend
immun
respons
coval
link
carrier
protein
therebi
provid
helper
tcell
activ
result
glycoconjug
vaccin
induc
better
antibodi
respons
effect
age
group
today
effect
glycoconjug
vaccin
avail
haemophilu
influenza
pneumococcu
meningococcu
type
c
w
hepat
b
viru
hbv
human
papillomaviru
hpv
easili
cultur
vitro
vaccin
product
firstgener
hbv
vaccin
consist
purifi
hbv
surfac
antigen
blood
infect
donor
progress
molecular
biolog
allow
improv
vaccin
hbv
recent
develop
new
vaccin
prevent
hpv
vaccin
made
purifi
recombin
protein
antigen
form
noninfecti
virallik
particl
vlp
last
decad
progress
genom
also
contribut
vaccin
develop
unlik
meningococci
neisseria
meningitidi
type
b
menb
cover
capsular
polysaccharid
similar
polysaccharid
present
human
tissu
therefor
poorli
immunogen
menb
capsular
polysaccharid
use
glycoconjug
vaccin
unlik
effici
done
type
c
w
pace
make
vaccin
base
recombin
protein
also
challeng
extrem
antigen
variat
seen
circul
menb
strain
problem
solv
ration
select
candid
antigen
base
genom
inform
call
revers
vaccinolog
pizza
et
al
rappuoli
process
three
protect
antigen
common
multipl
menb
strain
express
recombin
protein
combin
menb
outer
membran
vesicl
omv
result
first
univers
vaccin
type
b
meningococcu
giuliani
et
al
vaccin
describ
given
healthi
subject
prevent
infect
addit
prevent
cancer
associ
chronic
infect
hpv
hbv
pineau
tiollai
romanowski
therapeut
use
vaccin
base
specif
antigen
associ
diseas
equal
success
despit
mani
attempt
cure
chronic
infect
cancer
howev
fda
approv
sipuleucelt
first
therapeut
vaccin
prostat
cancer
administr
sipuleucelt
differ
licens
prevent
vaccin
blood
cell
individu
prostat
cancer
patient
expos
prostat
antigen
prostat
acid
phosphatas
fuse
cytokin
gmcsf
reinfus
patient
plosker
although
immun
process
complex
expens
sipuleucelt
repres
mileston
may
pave
way
wider
use
cancer
vaccin
immunotherapi
base
innov
technolog
allow
simpler
immun
method
sever
cancer
vaccin
candid
base
recombin
antigen
viral
vector
advanc
develop
promis
phase
ii
result
kruit
et
al
confirm
partial
efficaci
larger
phase
iii
trial
next
step
combin
cancer
vaccin
addit
immunotherapi
monoclon
antibodi
act
neg
regul
immun
respons
eg
hodi
et
al
hamid
et
al
recent
describ
scienc
breakthrough
year
couzinfrankel
summari
applic
innov
technolog
last
centuri
allow
develop
novel
vaccin
target
new
diseas
new
target
popul
next
paragraph
review
focu
vaccin
prevent
infecti
diseas
give
overview
recent
clinic
trial
import
vaccin
candid
develop
discuss
target
popul
adequ
protect
vaccin
final
assess
novel
immun
technolog
develop
today
address
medic
need
centuri
giv
wwwwhointimmunizationgivsen
routin
immun
program
protect
world
children
number
infecti
diseas
previous
claim
million
live
year
travel
vaccin
offer
possibl
avoid
number
infecti
diseas
may
encount
abroad
howev
satisfactori
vaccin
yet
develop
sever
widespread
lifethreaten
infect
human
immunodefici
viru
hiv
affect
million
peopl
worldwid
uniaid
global
report
wwwunaidsorgen
malaria
tuberculosi
kill
almost
million
peopl
everi
year
report
wwwwhoint
exampl
pathogen
may
prevent
vaccin
vaccin
yet
avail
hepat
c
viru
hcv
dengu
respiratori
syncyti
viru
rsv
cytomegaloviru
cmv
group
b
streptococcu
gb
staphylococcu
aureu
pseudomona
aeruginosa
fig
vaccin
develop
twentieth
centuri
effect
protect
pathogen
low
degre
antigen
variabl
pathogen
exist
multipl
strain
exhibit
moder
degre
antigen
variabl
requir
multival
vaccin
success
exampl
possibl
pneumococcu
conjug
polysaccharid
vaccin
develop
cover
progress
broader
number
serogroup
prymula
schuerman
duggan
extrem
situat
exist
season
influenza
vaccin
organ
rapidli
alter
multival
must
redevelop
everi
year
incorpor
influenza
surfac
antigen
predict
circul
diseas
variant
howev
vaccin
success
protect
pathogen
character
high
mutat
rate
hiv
hcv
abl
evad
antibodi
respons
modifi
target
antigen
cours
infect
addit
licens
vaccin
believ
prevent
infect
gener
neutral
opson
antibodi
nonetheless
crucial
contribut
cell
instanc
helper
cell
contribut
effici
bcell
activ
influenc
antibodi
isotyp
switch
glossari
vaccin
biolog
prepar
enhanc
immun
diseas
either
prevent
prophylact
vaccin
treat
diseas
therapeut
vaccin
word
vaccin
origin
latin
variola
vaccina
cowpox
edward
jenner
demonstr
could
prevent
smallpox
human
immunotherapi
treatment
diseas
induc
enhanc
suppress
immun
respons
live
attenu
viabl
infecti
organ
reduc
virul
abil
caus
diseas
infecti
agent
may
attenu
vitro
passag
chemic
genet
mean
inactiv
kill
infecti
organ
whole
organ
may
inactiv
chemic
thermal
mean
subunit
vaccin
vaccin
deriv
compon
diseasecaus
organ
specif
protein
polysaccharid
polysaccharid
vaccin
vaccin
deriv
complex
sugar
capsular
polysaccharid
cover
surfac
encapsul
bacteria
conjug
vaccin
vaccin
deriv
coval
linkag
conjug
polysaccharid
carrier
protein
enhanc
immunogen
combin
vaccin
vaccin
differ
diseasecaus
organ
combin
one
formul
uniqu
immun
synthet
vaccin
vaccin
base
synthet
compon
nucleic
acid
synthet
peptid
polysaccharid
antigen
recombin
deriv
use
recombin
dna
technolog
revers
vaccinolog
method
produc
vaccin
first
studi
genom
inform
organ
silico
determin
gene
code
candid
antigen
protein
follow
vitro
vivo
test
candid
select
vaccin
develop
serotyp
type
microorgan
determin
constitu
antigen
serogroup
group
serotyp
one
antigen
common
neutral
antibodi
antibodi
reduc
abolish
biolog
activ
solubl
antigen
live
microorgan
opson
antibodi
antibodi
caus
bacteria
foreign
cell
becom
suscept
action
phagocyt
nosocomi
acquir
antibioticresist
bacteria
hospit
acquir
bacteria
longer
suscept
treatment
antibiot
activ
target
cell
eg
macrophag
neutrophil
eosinophil
exampl
differenti
induct
versu
cell
lead
improv
protect
whole
cell
bacteri
vaccin
like
pertussi
ross
et
al
also
direct
contribut
cellular
immun
form
cytotox
cell
shown
play
role
liveattenu
vaccin
convent
technolog
limit
success
prevent
infect
control
predominantli
cell
tuberculosi
challeng
futur
even
greater
infect
caus
highli
variabl
pathogen
may
prevent
antibodi
alon
requir
correct
combin
qualiti
humor
cellular
immun
respons
mani
pathogen
natur
infect
lead
immun
host
reinfect
mani
highli
success
vaccin
method
prevent
natur
acquir
smallpox
call
variol
discov
india
ad
use
also
china
western
asia
method
consist
inocul
pustul
materi
smallpoxinfect
patient
healthi
individu
introduc
europ
ladi
mari
wortley
montagu
first
real
vaccin
practic
introduc
edward
jenner
use
pustul
materi
human
infect
cowpox
protect
smallpox
embo
molecular
medicin
vol
author
liveattenu
inactiv
vaccin
may
reli
direct
mimicri
natur
immun
induc
pathogen
howev
satisfactori
vaccin
yet
develop
infect
fail
elicit
protect
immun
respons
caus
organ
instanc
diseas
induc
steril
immun
natur
infect
eg
malaria
rsv
p
aeruginosa
caus
persist
latent
infect
eg
hiv
hcv
aureu
vaccineinduc
protect
immun
respons
must
go
beyond
mechan
natur
evolv
furthermor
immun
respons
determin
certain
viral
agent
rsv
dengu
viru
actual
exacerb
diseas
low
level
antibodi
give
rise
enhanc
infect
kim
et
al
halstead
depend
type
infect
prevent
effect
vaccin
may
requir
induct
differ
humor
cellular
immun
effector
mechan
lack
understand
pathogenesi
infect
organ
absenc
good
anim
model
also
lack
correl
protect
factor
contribut
difficulti
develop
challeng
vaccin
among
despit
decad
concert
effort
vaccin
research
hiv
malaria
tuberculosi
repres
diseas
current
highli
effect
candid
vaccin
close
licensur
recent
failur
latephas
clinic
trial
highlight
difficulti
encount
hiv
hiv
fourth
largest
killer
world
today
annual
death
toll
approxim
million
new
infect
daili
koff
et
al
nearli
three
decad
pass
sinc
identif
hiv
caus
organ
aid
attempt
develop
effect
vaccin
highli
variabl
retroviru
repeatedli
stymi
challeng
develop
hiv
vaccin
multifold
includ
global
variabl
hiv
lack
valid
anim
model
correl
protect
immun
natur
protect
immun
respons
hiv
reservoir
infect
cell
confer
integr
hiv
genom
host
destruct
immun
cell
hiv
infect
drive
forc
hiv
vaccin
design
move
either
target
antibodi
respons
protein
antigen
vaccin
cellmedi
respons
viral
vector
genebas
vaccin
respect
vaccin
attempt
elicit
cellular
humor
immun
respons
heterolog
primeboost
regimen
initi
hiv
vaccin
trial
attempt
elicit
protect
antibodi
respons
solubl
envelop
protein
fail
show
efficaci
flynn
et
al
pitisuttithum
et
al
two
clinic
trial
step
phambili
conduct
candid
multival
recombin
adenoviru
vector
express
multipl
antigen
includ
clade
b
gag
pol
nef
lack
env
intend
induc
cellular
respons
despit
induct
gagand
polspecif
tcell
respons
major
subject
earli
viral
load
decreas
buchbind
et
al
gray
et
al
gray
et
al
addit
increas
risk
acquisit
observ
subset
vaccine
preexist
antibodi
step
trial
buchbind
et
al
mcelrath
et
al
recent
failur
discontinu
efficaci
trial
repres
anoth
hard
blow
hiv
vaccin
advanc
trial
use
dna
prime
vector
boost
multipl
antigen
modifi
env
gene
clade
b
c
gag
pol
gene
clade
b
elicit
antibodi
tcell
respons
perform
subject
without
preexist
antibodi
vaccin
fail
show
protect
despit
preselect
seroneg
subject
trend
toward
infect
among
vaccine
observ
although
statist
signific
http
html
lack
efficaci
trial
suggest
futur
hiv
includ
list
agent
infecti
diseas
vaccin
yet
avail
effect
vaccin
would
benefici
also
includ
therapeut
vaccin
chronic
infecti
diseas
well
noncommunic
patholog
autoimmun
diseas
cancer
allergi
advanc
clinic
trial
vaccin
strategi
avoid
human
adenovirusbas
vector
approach
success
approach
base
combin
two
vaccin
recombin
canarypox
vector
envelop
subunit
primeboost
strategi
vaccin
administ
thailand
socal
trial
protect
subject
hiv
acquisit
rerksngarm
et
al
hayn
et
al
studi
show
first
time
prevent
hiv
infect
achiev
vaccin
followup
studi
show
antibodi
direct
variabl
region
envelop
correl
invers
infect
risk
hayn
et
al
known
long
time
antibodi
crossneutr
infect
multipl
hiv
strain
recent
novel
technolog
investig
bcell
repertoir
allow
isol
sever
broadli
neutral
human
monoclon
antibodi
result
natur
infect
antibodi
character
high
degre
somat
hypermut
compar
germlin
suggest
develop
requir
longterm
antigen
exposur
character
crossneutr
antibodi
led
identif
conserv
epitop
hiv
env
protein
may
use
design
new
vaccin
capabl
confer
broader
protect
review
corti
lanzavecchia
kwong
et
al
furthermor
recent
studi
demonstr
therapeut
potenti
passiv
administr
combin
neutral
monoclon
antibodi
control
chronic
shiv
infect
rhesu
monkey
model
barouch
et
al
shingai
et
al
find
suggest
vaccin
capabl
elicit
crossneutr
antibodi
target
differ
epitop
env
trimer
may
control
viremia
chronic
infect
hiv
patient
nonetheless
design
immunogen
capabl
elicit
hiv
crossneutr
antibodi
still
present
consider
challeng
particular
consid
hypermut
human
antibodi
discov
far
approxim
million
clinic
case
malaria
report
everi
year
almost
one
million
death
occur
subsaharan
africa
mostli
among
children
http
wwwwhoint
robust
pipelin
malaria
vaccin
candid
variou
preclin
clinic
phase
develop
illustr
tabl
vaccin
http
wwwwhointvaccineresearch
linksrainbowenindexhtml
major
vaccin
base
recombin
protein
half
consist
singl
antigen
plasmodium
falciparum
caus
agent
malaria
complex
life
cycl
numer
antigen
could
feasibl
target
protect
respons
distinct
phase
cycl
antigen
often
polymorph
candid
rt
advanc
start
largest
phase
iii
malaria
vaccin
trial
date
rt
combin
portion
circumsporozoit
protein
surfac
protein
help
parasit
invad
human
liver
cell
hepat
b
surfac
antigen
also
includ
adjuv
improv
immun
respons
phase
ii
studi
rt
show
efficaci
first
malaria
episod
children
bejon
et
al
howev
efficaci
vaccin
limit
durat
detect
year
vaccin
olotu
et
al
bejon
et
al
first
result
phase
iii
trial
confirm
protect
age
group
howev
lower
vaccin
efficaci
observ
children
includ
analysi
suggest
agedepend
differenti
immun
respons
vaccin
agnandji
et
al
final
result
expect
result
far
suggest
target
age
group
rt
intend
efficaci
sever
malaria
low
model
estim
benefit
implement
rt
routin
infant
immun
predict
vaccin
could
nonetheless
impact
save
signific
number
live
brook
et
al
although
vaccin
shown
mediocr
efficaci
effect
declin
time
still
expect
becom
first
malaria
vaccin
receiv
regulatori
approv
bouchi
focu
vaccin
develop
move
next
gener
malaria
vaccin
yet
clear
characterist
new
vaccin
evalu
understand
immun
correl
aid
develop
field
basic
human
immunolog
system
biolog
may
provid
essenti
inform
improv
perform
rt
fulli
optim
vaccin
candid
bacil
bcg
vaccin
one
first
vaccin
develop
calmett
et
al
administ
billion
subject
thu
far
yet
mycobacterium
tuberculosi
respons
human
death
singl
pathogen
today
ottenhoff
kaufmann
nearli
million
new
case
million
death
annual
lawn
zumla
bcg
vaccin
effect
infant
sever
tuberculosi
tb
diseas
immun
wane
time
bcg
effect
booster
control
tb
requir
tcell
immun
respons
proven
challeng
develop
novel
effect
vaccin
approxim
tb
vaccin
candid
current
evalu
clinic
trial
design
prevent
activ
tb
diseas
kaufmann
vaccin
either
live
recombin
mycobacteria
vaccin
genet
engin
increas
efficaci
andor
safeti
aim
substitut
bcg
ii
adjuv
protein
viral
vector
express
antigen
aim
boost
immun
respons
induc
bcg
prime
advanc
tb
vaccin
candid
viral
vector
vaccin
test
phase
iib
efficaci
trial
howev
current
gener
vaccin
candid
fulfil
expect
recent
result
first
efficaci
trial
infant
use
modifi
vaccinia
ankara
viru
express
antigen
show
vaccin
candid
safe
provid
signific
protect
tb
given
booster
infant
receiv
bcg
birth
tameri
et
al
anoth
approach
base
adjuv
recombin
protein
antigen
well
toler
immunogen
phase
trial
lerouxroel
et
al
current
assess
phase
ii
trial
nextgener
vaccin
design
induc
steril
immun
kaufmann
current
tool
avail
vaccin
develop
potent
adjuv
recombin
vector
either
recombin
mycobacteria
heterolog
viral
carrier
embo
molecular
medicin
vol
author
use
heterolog
primeboost
combin
effect
tb
vaccin
may
inde
possibl
show
somewhat
promis
result
anim
earli
clinic
trial
recent
clinic
trial
vaccin
aureu
dengu
viru
given
disappoint
result
due
lack
efficaci
safeti
concern
first
aureu
vaccin
test
human
contain
type
capsular
polysaccharid
conjug
nontox
recombin
pseudomona
aeruginosa
exotoxin
staphvax
appear
confer
limit
shortterm
protect
bacteremia
hemodialysi
patient
shinefield
et
al
larger
phase
iii
clinic
trial
fail
demonstr
signific
efficaci
jansen
et
al
recent
vaccin
consist
singl
highli
conserv
aureu
antigen
isdb
shown
immunogen
healthi
adult
patient
undergo
chronic
hemodialysi
harro
et
al
harro
et
al
moustafa
et
al
increas
specif
antiisdb
igg
titer
observ
postvaccin
maintain
year
hemodialysi
patient
howev
subsequ
larg
phase
iibiii
studi
evalu
efficaci
safeti
preoper
vaccin
patient
undergo
cardiothorac
surgeri
interrupt
vaccin
reduc
rate
seriou
postop
aureu
infect
fowler
et
al
date
aureu
vaccin
candid
design
elicit
antibodi
product
one
antigen
compon
bacterium
howev
protect
immun
aureu
yet
understood
failur
passiv
immun
strategi
clinic
trial
schaffer
lee
ohlsen
lorenz
otto
suggest
humor
immun
may
import
insuffici
prevent
aureu
infect
furthermor
patient
quantit
qualit
tcell
neutrophil
disord
increas
suscept
recur
aureu
infect
suggest
cellmedi
immun
particular
respons
may
play
import
role
proctor
spellberg
daum
current
work
focus
understand
correl
protect
aureu
human
serv
develop
nextgener
vaccin
vaccin
prefer
combin
antigen
stimul
humor
cellular
respons
aureu
dengu
fever
complex
flavivir
diseas
caus
four
antigen
distinct
dengu
virus
infect
million
peopl
per
year
therapi
vaccin
current
avail
dengu
viru
present
particular
conundrum
vaccin
develop
due
safeti
concern
associ
potenti
increas
rate
sever
dengu
diseas
incomplet
immun
respons
associ
poorli
protect
low
neutral
antibodi
level
four
serotyp
halstead
thu
goal
dengu
viru
vaccin
develop
produc
balanc
protect
antibodi
respons
four
dengu
viru
denv
serotyp
avoid
incomplet
immun
respons
theoret
could
facilit
pathogenesi
current
sever
kind
dengu
viru
vaccin
develop
one
consist
four
recombin
liveattenu
chimer
yellow
feverbas
dengu
viru
cyd
reach
late
stage
clinic
efficaci
trial
heinz
stiasni
recent
phase
iib
trial
diseas
incid
serotyp
reduc
upon
vaccin
tetraval
cyd
vaccin
diseas
caus
also
reduc
albeit
lesser
extent
efficaci
preval
serotyp
caus
infect
studi
sabchareon
et
al
monoval
vaccin
show
excel
immunogen
phase
trial
guirakhoo
et
al
howev
neutral
titer
lower
tetraval
formul
monkey
previou
human
studi
guy
et
al
morrison
et
al
poo
et
al
light
result
phase
iib
studi
sabchareon
et
al
show
high
level
neutral
antibodi
lack
protect
surpris
author
suggest
novel
genotyp
circul
within
thailand
diminish
crossreact
elicit
antibodi
howev
result
also
interpret
evid
possibl
viral
interfer
trial
halstead
swaminathan
et
al
vaccin
administ
children
adult
dengu
endem
nonendem
area
sever
diseas
trial
particip
report
howev
safeti
efficaci
inextric
link
dengu
viru
vaccin
theoret
risk
vaccinerel
advers
event
immun
enhanc
infect
necessit
longlast
protect
immun
respons
four
dengu
serotyp
simultan
induc
societi
progress
see
lower
proport
children
young
peopl
higher
proport
elderli
peopl
increas
life
expect
centuri
mainli
associ
reduct
infecti
diseas
mortal
children
larg
due
vaccin
decreas
oldag
mortal
due
new
therapi
sever
factor
includ
reduc
lifetim
exposur
inflamm
finch
crimmin
rappuoli
et
al
major
vaccin
current
avail
develop
pediatr
vaccin
today
societi
clearli
quit
differ
medic
need
vaccin
repres
potenti
key
primari
prevent
divers
age
target
group
includ
adult
elderli
adolesc
pregnant
women
peopl
suffer
chronic
immunecompromis
diseas
fig
senesc
immun
system
make
elderli
vulner
infect
wane
vaccin
respons
may
requir
regular
booster
vaccin
life
expect
increas
major
caus
infect
death
shift
childhood
diseas
infecti
noninfecti
chronic
ill
adulthood
infect
nosocomi
acquir
antibioticresist
bacteria
frequent
elderli
age
group
would
desir
prevent
vaccin
respons
vaccin
may
reduc
elderli
due
age
immun
system
formul
adjuv
strategi
amplif
immun
respons
may
requir
addit
anticanc
strategi
could
target
adult
elderli
vaccin
caus
agent
divers
infectionassoci
tumor
hbv
hpv
helicobact
pylori
rupnow
et
al
pineau
tiollai
romanowski
novel
therapeut
vaccin
selfantigen
overexpress
colon
breast
prostat
cancer
inde
first
decad
centuri
saw
novel
prophylact
therapeut
cancer
vaccin
licens
siddiqui
perri
keam
harper
plosker
matern
vaccin
simultan
protect
mother
develop
fetu
newborn
first
month
life
placent
antibodi
transfer
today
young
women
less
expos
infecti
agent
may
suboptim
respons
hivposit
mother
mean
newborn
often
inadequ
protect
via
matern
antibodi
varieti
pathogen
includ
cmv
influenza
viru
gb
hbv
meningococcu
type
b
c
mainli
b
c
europ
bordetella
pertussi
rsv
rotaviru
tetanu
success
safeti
matern
vaccin
tetanu
influenza
pertussi
recommend
use
pregnanc
recent
shown
roper
et
al
zaman
et
al
demich
et
al
liveattenu
vaccin
rubella
influenza
yellow
fever
contraind
pregnanc
due
potenti
complic
attenu
agent
reach
fetu
studi
complet
inadvert
immun
pregnanc
detect
advers
event
nasidi
et
al
castillosolorzano
et
al
moro
et
al
number
addit
matern
vaccin
also
pipelin
could
use
combat
neonat
infect
gb
rsv
heali
travel
face
exposur
mani
infect
encount
abroad
vaccin
offer
protect
signific
need
effect
vaccin
dengu
fever
cholera
etec
malaria
shigella
paratyphoid
fever
vaccin
suboptim
vaccin
avail
furthermor
develop
countri
million
children
die
vaccineprevent
diseas
everi
year
effect
vaccin
often
avail
addit
need
vaccin
malaria
tuberculosi
hiv
lowincom
countri
socal
neglect
tropic
diseas
includ
hookworm
infect
dengu
fever
schistosomiasi
leishmaniasi
nontyphoid
salmonellosi
new
gener
antipoverti
vaccin
requir
number
initi
launch
address
avail
present
vaccin
develop
vaccin
neglect
diseas
review
rappuoli
et
al
peopl
chronic
diseas
autoimmun
diseas
immunosuppress
disord
well
peopl
affect
hiv
individu
chronic
respiratori
cardiac
diseas
special
vaccin
need
specif
condit
immunecompromis
subject
liveattenu
vaccin
may
toler
well
inactiv
subunit
vaccin
possibl
potent
adjuv
may
requir
elicit
protect
respons
struggl
develop
effect
vaccin
sever
infecti
agent
progress
immunolog
microbiolog
genet
structur
biolog
provid
new
set
tool
approach
nextgener
vaccin
develop
fig
new
technolog
greatli
facilit
identif
novel
protect
antigen
either
highthroughput
discoveri
strategi
ration
design
nextgener
vaccin
like
show
improv
key
area
develop
novel
class
vaccin
adjuv
promot
better
protect
humor
cellular
immun
respons
optim
present
antigen
immun
system
order
shape
immun
respons
furthermor
manufactur
vaccin
use
highli
character
synthet
method
product
vaccin
becom
much
safer
possibl
develop
vaccin
infecti
agent
diseas
could
effect
target
use
earli
vaccin
method
adjuv
licens
human
vaccin
base
aluminum
salt
oil
water
emuls
develop
empir
mechan
action
partial
understood
de
gregorio
et
al
howev
recent
year
understand
molecular
mechan
innat
immun
respons
dramat
increas
lead
discoveri
new
class
receptor
tolllik
receptor
tlr
nodlik
receptor
nlr
riglik
receptor
rlr
hoeb
et
al
akira
et
al
molecul
evolv
sens
microbi
infect
trigger
immun
respons
adapt
invad
pathogen
importantli
innat
immun
reaction
trigger
receptor
also
requir
enhanc
modul
antigenspecif
immun
newli
discov
innat
immun
receptor
ideal
target
new
gener
ration
design
vaccin
adjuv
may
great
impact
vaccin
develop
larg
number
novel
adjuv
target
specif
innat
immun
receptor
test
human
clinic
trial
review
de
gregorio
et
al
year
ago
one
agonist
call
monophosphoryl
lipid
mpl
coadsorb
alum
hpv
antigen
licens
human
use
giannini
et
al
report
effect
adjuv
human
improv
vaccin
efficaci
increas
antibodi
titer
tcell
frequenc
improv
durat
protect
respons
increas
crossprotect
differ
strain
variant
bacteri
viral
pathogen
antigen
dose
spare
reduc
number
dose
requir
reach
protect
antibodi
titer
addit
adjuv
modul
qualiti
antibodi
isotyp
tcell
respons
trigger
immun
tailor
pathogen
new
adjuv
potenti
improv
efficaci
exist
vaccin
novel
prevent
therapeut
vaccin
address
unmet
medic
need
preclin
human
studi
demonstr
differ
adjuv
synerg
combin
vaccin
formul
make
adjuv
even
attract
vaccin
develop
exampl
adjuv
use
rtss
malaria
vaccin
describ
made
mix
liposom
saponin
call
mpl
howev
special
attent
must
dedic
safeti
profil
novel
adjuv
fact
agonist
innat
receptor
potenti
toxic
must
administ
way
optim
adjuvant
reduc
local
system
reactogen
two
characterist
adjuv
like
intrins
link
must
care
balanc
viral
vector
base
adenovirus
pox
virus
de
cassan
draper
mimic
live
infect
express
antigen
situ
immun
therebi
facilit
induct
strong
tcell
respons
includ
cytotox
lymphocyt
type
respons
desir
intracellular
highli
variabl
pathogen
addit
target
pathogeninfect
cell
versu
pathogen
target
epitop
conserv
differ
strain
liu
broad
spectrum
replic
nonrepl
vector
avail
varieti
attenu
virus
employ
vector
includ
vaccinia
pox
virus
adenoviru
singlestrand
rna
viru
replicon
vector
alphavirus
coronavirus
picornavirus
flavivirus
influenza
virus
rhabdovirus
paramyxovirus
viral
vector
undergon
extens
preclin
assess
wide
spectrum
diseas
test
numer
clinic
trial
studi
reveal
hierarchi
potenc
individu
vector
viral
vector
advantag
limit
rang
applic
review
rollier
et
al
choic
appropri
vector
use
develop
vaccin
depend
biolog
infecti
agent
target
whether
vaccin
intend
prevent
infect
boost
immun
alreadyinfect
individu
prior
exposur
target
popul
vector
number
size
gene
insert
need
suitabl
largescal
manufactur
complianc
regulatori
requir
licens
sever
veterinari
viral
vector
vaccin
poulet
et
al
weyer
et
al
highlight
potenti
technolog
howev
still
recombin
viru
vector
vaccin
licens
human
reason
includ
limit
potenc
due
preexist
antivector
immun
concern
safeti
alreadi
discuss
recombin
vector
hiv
trial
addit
applic
infecti
diseas
viral
vector
employ
cancer
vaccin
sever
clinic
trial
show
encourag
result
one
advanc
approach
base
primeboost
immun
use
two
differ
viral
vector
vaccinia
viru
fowlpox
respect
express
prostat
cancer
antigen
psa
three
differ
costimulatori
molecul
vaccin
strategi
demonstr
increas
median
surviv
reduct
death
rate
metastat
castrationresist
prostat
cancer
patient
phase
ii
trial
kantoff
et
al
also
interest
use
liveattenu
bacteria
usual
salmonella
listeria
spp
vector
present
heterolog
antigen
vaccin
allow
immun
mucos
rout
specif
target
profession
antigenpres
cell
locat
induct
site
immun
system
humor
cellular
immun
respons
potenti
prime
approach
novel
approach
exploit
intracellular
bacteria
deliveri
vector
dna
vaccin
toussaint
et
al
key
advanc
synthet
vaccinolog
use
nucleic
acidbas
vaccin
combin
advantag
situ
express
antigen
safeti
subunit
vaccin
vaccin
base
dna
rna
inhibit
preexist
antivector
immun
like
case
viral
vector
manufactur
nucleic
acidbas
vaccin
also
offer
potenti
rel
simpl
inexpens
year
attent
focus
dna
vaccin
shown
potent
wide
varieti
anim
speci
sever
product
licens
commerci
veterinari
use
draghiaakli
et
al
davi
et
al
garver
et
al
grosenbaugh
et
al
human
howev
show
much
promis
preclin
model
dna
vaccin
shown
reduc
disappoint
potenc
clinic
review
ferraro
et
al
like
due
poor
deliveri
vaccin
dna
human
cell
insuffici
stimul
human
immun
system
latest
gener
dna
vaccin
may
reli
improv
deliveri
either
use
electropor
sardesai
weiner
coadministr
gene
encod
immunostimulatori
cytokin
lori
et
al
flingai
et
al
overcom
limit
recent
electropor
dna
vaccin
encod
hpv
antigen
induc
good
antibodi
tcell
respons
exhibit
cytolyt
function
human
bagarazzi
et
al
furthermor
mix
regimen
immun
dna
vaccin
effect
prime
band
tcell
respons
earli
studi
reveal
potenc
tcell
respons
enhanc
initi
immun
plasmid
dna
follow
viral
vector
encod
antigen
socal
heterolog
primeboost
regimen
potent
either
dna
viral
vector
alon
independ
order
administr
schneider
et
al
recent
heterolog
primeboost
regimen
mainli
use
viral
vector
dna
vaccin
prime
follow
boost
proteinbas
vaccin
exampl
primeboost
strategi
studi
subject
prime
canarypox
vector
encod
gag
env
proteas
boost
subunit
vaccin
rerksngarm
et
al
immun
schedul
result
induct
strong
cellular
immun
respons
associ
higher
specif
antibodi
respons
vaccin
target
compar
homolog
immun
overcom
issu
antivector
immun
rna
vaccin
base
mrna
rna
replicon
may
offer
certain
advantag
plasmid
dna
viral
vector
rna
vaccin
activ
cytoplasm
requir
deliveri
nucleu
therefor
avoid
potenti
issu
dna
integr
howev
increas
suscept
degrad
rna
compar
dna
requir
addit
stabil
technolog
geall
et
al
date
sever
exploratori
trial
cancer
patient
mrna
vaccin
result
induct
antitumor
immun
demonstr
proof
concept
human
weid
et
al
weid
et
al
rittig
et
al
rna
vaccin
also
engin
rna
replicon
deriv
certain
rna
virus
lack
viral
structur
protein
capabl
selfrepl
deliveri
cytoplasm
geall
et
al
geall
et
al
rna
amplif
process
lead
doublestrand
rna
intermedi
known
potent
stimul
innat
immun
therefor
may
inher
adjuvant
respect
mrna
vaccin
dna
vaccin
formul
enabl
deliveri
technolog
import
area
research
rna
vaccin
recent
public
report
collabor
effort
develop
rapid
process
synthet
vaccin
viru
gener
one
first
realworld
product
synthet
biolog
dormitz
et
al
influenza
vaccin
prepar
administ
human
sinc
challeng
within
field
continu
drive
advanc
technolog
develop
new
approach
recent
studi
three
major
technic
barrier
rapid
reliabl
respons
pandem
flu
address
speed
synthes
dna
cassett
drive
product
influenza
rna
genom
segment
accuraci
rapid
gene
synthesi
yield
ha
vaccin
virus
implement
synthet
seed
gener
influenza
vaccin
manufactur
would
enabl
highyield
vaccin
viru
avail
manufactur
test
scaleup
process
optim
within
day
month
new
viru
first
detect
detail
threedimension
structur
domain
organ
dynam
surfac
protein
pathogen
offer
molecular
target
guid
design
effect
vaccin
better
immunogen
stabil
nativ
conform
combin
expos
andor
improv
immunogen
epitop
review
back
langedijk
burton
et
al
kulp
schief
import
goal
structur
vaccinolog
stabil
conform
antigen
capabl
elicit
protect
respons
select
present
conserv
determin
complex
variabl
antigen
order
focu
immun
respons
conserv
epitop
f
protein
rsv
major
target
structurebas
vaccin
design
f
glycoprotein
adopt
two
conform
viru
prefus
infect
postfus
infect
recogn
neutral
antibodi
review
mclellan
et
al
determin
structur
postfus
state
rsv
f
glycoprotein
allow
engin
stabl
f
immunogen
abl
elicit
neutral
antibodi
swanson
et
al
recent
elucid
crystal
structur
prefus
state
rsv
f
complex
neutral
antibodi
mclellan
et
al
pave
way
structurebas
design
first
stabl
prefus
f
antigen
superior
immunogen
compar
postfus
antigen
mclellan
et
al
one
potenti
applic
structur
vaccinolog
design
improv
antigen
prevent
hiv
infect
env
protein
heterodim
made
nativ
present
trimer
sole
target
hiv
neutral
antibodi
howev
due
instabl
trimer
solut
immunodomin
variabl
region
candid
mani
structur
studi
ration
immunogen
design
review
burton
et
al
approxim
hivinfect
individu
develop
broadli
neutral
antibodi
bnab
respons
time
last
year
mani
relev
epitop
defin
map
use
novel
technolog
review
corti
lanzavecchia
find
serv
identifi
highli
conserv
invari
structur
target
bnab
serv
ration
immunogen
design
variou
approach
integr
structur
sequenc
inform
famili
bnab
recent
enabl
creation
germlinetarget
immunogen
bind
activ
germlin
b
cell
order
initi
elicit
antibodi
jardin
et
al
although
bnab
respons
success
elicit
hiv
vaccin
candid
date
find
trial
antibodi
respons
could
contribut
protect
rerksngarm
et
al
hayn
et
al
encourag
furthermor
recent
elucid
crystal
cryoem
structur
env
trimer
lyumki
et
al
open
new
paragraph
structurebas
design
nextgener
improv
immunogen
critic
question
success
vaccin
futur
technolog
alon
combin
must
use
elicit
protect
respons
answer
differ
pathogen
base
integr
differ
immun
effector
mechan
appropri
qualiti
end
import
assess
impact
novel
vaccin
technolog
human
trial
correl
multipl
immun
readout
protect
progress
genom
allow
gener
huge
amount
highthroughput
data
human
blood
sampl
includ
rna
protein
express
profil
bcell
repertoir
analysi
singl
cell
analysi
analysi
genom
polymorph
system
biolog
requir
interrog
genom
data
identifi
molecular
signatur
correl
immunolog
analys
obtain
subject
classic
immunolog
assay
antibodi
tcell
character
pulendran
et
al
studi
vaccin
respons
yellow
fever
influenza
vaccin
approach
alreadi
success
appli
lead
identif
protect
signatur
predict
immunogen
vaccin
human
subject
gaucher
et
al
querec
et
al
final
goal
use
system
biolog
interrog
human
vaccin
respons
identifi
biomark
safeti
efficaci
vaccin
biomark
potenti
acceler
time
vaccin
develop
allow
select
promis
vaccin
candid
earli
exploratori
clinic
trial
proceed
long
expens
efficaci
trial
involv
larg
number
subject
begin
centuri
alreadi
seen
new
vaccin
licens
becom
avail
due
develop
novel
approach
novel
technolog
viruslik
particl
allow
develop
vaccin
hpv
siddiqui
perri
keam
harper
revers
vaccinolog
mine
genom
sequenc
highthroughput
antigen
discoveri
success
allow
develop
novel
multicompon
recombin
vaccin
meningococcu
type
b
giuliani
et
al
first
therapeut
vaccin
base
blood
cell
infus
licens
prostat
cancer
plosker
sever
tool
develop
case
alreadi
test
human
trial
greatli
support
discoveri
ration
design
novel
vaccin
difficult
target
hiv
malaria
tb
dengu
aureu
convent
technolog
fail
hope
thank
technolog
infecti
diseas
prevent
vaccin
children
adolesc
adult
elderli
pregnant
women
immunocompromis
subject
novel
vector
adjuv
may
also
allow
develop
therapeut
vaccin
treat
differ
form
cancer
chronic
infect
inflammatori
disord
develop
innov
immun
regim
novel
deliveri
technolog
provid
unpreced
mean
augment
shape
immun
respons
experi
recent
clinic
trial
taught
us
quantiti
magnitud
immun
respons
import
qualiti
flavor
respons
equal
import
predict
immunogen
necessarili
translat
predict
protect
mani
elus
target
vaccin
develop
one
challeng
gap
fill
identifi
biomark
correl
protect
immedi
goal
set
exploit
trial
undertaken
date
attempt
identifi
signatur
vaccin
efficaci
guid
earli
select
promis
vaccin
candid
futur
understand
respons
desir
necessari
protect
induc
vaccin
unlock
door
ration
design
effect
nextgener
vaccin
